Pilot Study of Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies.
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 Apr 2016 Treatment arms changed from 2 to 1, trial focus changed from AR to TU.
- 13 Apr 2016 Status changed from active, no longer recruiting to completed.